Short answer
Strata Critical Medical, Inc. (SRTA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026.
Strata Critical Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026
- Detailed results and management commentary available in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $72.5M, up 60.7% YoY, with Clinical revenue $24.3M and organic Clinical growth 15.1% sequentially
- Adjusted EBITDA $7.9M, margin 10.9%, up from $2.5M and 5.5% YoY, signaling improved operating leverage
- GAAP net loss $(10.5)M, driven partly by $5.0M accelerated trademark amortization and $5.5M non-cash liability revaluation
- Three Clinical acquisitions added more than $6M projected annualized Adjusted EBITDA, expanding perfusion and transplant recovery capabilities
- 2026 guidance raised: revenue $285-295M and Adjusted EBITDA $33-35M, while cash ended Q2 at $22.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Strata Critical Medical, Inc. 8-K filings
Get the next SRTA 8-K as it lands
Follow SRTA for push alerts, or ask the research agent what this filing means.